NatSec Tech Episode 75: Dr. Eric Schmidt on AI, Biotech, and Global Competition
51 snips
Apr 16, 2025 
In this engaging discussion, Eric Schmidt, former CEO of Google and chair of the Special Competitive Studies Project, dives into the fascinating convergence of AI and biotechnology. He highlights how AI is revolutionizing drug discovery, making processes faster and more efficient. The conversation also tackles the fierce competition between U.S. and Chinese tech industries, emphasizing the need for better funding in science. Additionally, Schmidt discusses the ethical implications of AI in healthcare and the importance of data integrity in preserving national security.
AI Snips
Chapters
Books
Transcript
Episode notes
Superintelligence Triggers New Threats
- AI superintelligence competition risks include IP theft, adversarial AI attacks, and kinetic attacks on data centers.
- Existing national security frameworks may be unprepared for these new digital and physical warfare domains.
Strengthen Tech Alliances
- The U.S. must strengthen partnerships with allies like Canada, Japan, and the EU to compete with China.
- Collaborative technology development boosts scale and supply chain security for national interests.
ASI Revolutionizes Biotech
- ASI could unlock biological mechanisms humans can't fully understand, advancing personalized medicine and curing diseases like cancer.
- Future researchers will rely on superintelligent AI daily, despite limited human comprehension of its reasoning.
